Our relentless dedication to accuracy, timeliness and regulatory rigor enables your therapeutic innovations to reach patients faster.
Our fully integrated GxP services are driven by your assay requirements and delivered by our veteran scientists – collaboratively, accurately, and on time.
Biomarkers
Immunogenicity
Pharmacokinetics & Pharmacodynamics (PK/PD)
Cell-Based Assays
Our team is comprised of recognized experts in effectively navigating complex and evolving opportunities for therapeutics innovation.
Biosimilars
Gene Therapy
Antibody Drug Conjugates (ADCs)
Immuno-oncology
Assessing humoral immunogenicity is an interesting challenge for adeno-associated virus (AAV)-based gene therapies. While most people are concerned about how to deal with pre-existing antibodies and their impact on cutpoints — such as using total antibody or neutralizing antibodies for inclusion/exclusion, including/excluding based on these results, and a number of other concerns — often times just coming up with the right assay format for measuring these antibodies is overlooked.
Explore the BioAgilytix way of thinking. Visit our Resource Center to learn more about our scientists’ expertise through case studies, blogs, industry articles and other scientific resources.
Quick links to our latest content offerings:
May 4, 2022The Broad Array of Vaccine Options for COVID-19
January 27, 2022Validation of qPCR Assays for Gene Therapy
May 9, 2022BioAgilytix appoints top healthcare executive David King to its Board of Directors
August 6, 2020Analytical Assays Determine Biosimilar Product Quality
December 2, 2019Immunogenicity Assessment of Gene Therapy Compounds
Platforms
Services
